KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Operating Income (2016 - 2025)

Pfizer (PFE) has disclosed Operating Income for 17 consecutive years, with $19.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income rose 136.72% to $19.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $21.2 billion, a 132.15% increase, with the full-year FY2025 number at $21.2 billion, up 156.6% from a year prior.
  • Operating Income was $19.0 billion for Q4 2025 at Pfizer, up from -$7.9 billion in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $19.0 billion in Q4 2025 to a low of -$51.8 billion in Q4 2024.
  • A 5-year average of -$1.3 billion and a median of $4.3 billion in 2021 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: surged 253.36% in 2021, then tumbled 465.19% in 2024.
  • Pfizer's Operating Income stood at $3.7 billion in 2021, then surged by 179.44% to $10.3 billion in 2022, then crashed by 236.88% to -$14.1 billion in 2023, then plummeted by 267.67% to -$51.8 billion in 2024, then surged by 136.72% to $19.0 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Operating Income are $19.0 billion (Q4 2025), -$7.9 billion (Q3 2025), and $5.1 billion (Q2 2025).